MAPT and Alzheimer disease: Such initiatives are essential to fully harness the potential of plasma p-Tau biomarkers in advancing precision medicine approaches for AD, ultimately enabling earlier diagnosis, improved patient stratification, and more effective therapeutic monitoring.